RRD International launched its new brand RRD Biopharma Development to reflect its offering of strategy-driven product development services to biopharmaceutical companies and investors.
  
The rebrand includes a new innovative Product Development Team (PDT) Model aimed at enabling biopharma companies with limited infrastructure to navigate the challenges of drug development efficiently and effectively resulting in more predictable product development outcomes.
 
RRD’s rapid start team partners with companies globally applying their experience to help accelerate drug development and reduce risk. Investing in the asset’s success, they aim to improve value and drive patient benefits.
 
Scott Tarrant, CEO of RRD Biopharma Development said, “Our unique approach uses insights and experience to strategize, optimize, and execute biopharmaceutical development, maximizing asset value and accelerating patient access to new medicines.nOur new, dynamic brand more accurately reflects and places emphasis on our development offering and the value that we deliver every day to our partners. The improved branding better communicates who we are and what we do which ultimately supports our growth and makes us a recognized development partner in the market.”